Enzymatica AB: Bulletin from annual general meeting 2018 in Enzymatica AB (publ)
26 Aprile 2018 - 3:30PM
Press release
26 April, 2018
Bulletin from annual general
meeting 2018 in Enzymatica AB (publ)
Enzymatica held its annual
general meeting today 26 April 2018 in Lund. The meeting resolved
upon the following:
Appropriation of
profit/loss
The annual general meeting resolved to adopt the income statements
and the balance sheets of the group and parent company and resolved
to carry forward the funds available at the annual general meeting
and, consequently, resolved not to distribute any dividend for the
financial year 2017.
Discharge from liability for the
members of the board of directors and the CEO
The annual general meeting discharged the board of directors and
the CEO from liability for the financial year 2017.
Board of directors and
auditor
The annual general meeting resolved to re-elect Bengt Baron, Mats K
Andersson, Guðmundur Pálmason, Marianne Dicander Alexandersson,
Sigurgeir Guðlaugsson and Louise Nicolin as members of the board of
directors. Bengt Baron was re-elected chairman of the board.
The annual general meeting resolved to appoint
Deloitte AB as auditor of the company for the period until the end
of the next annual general meeting. Deloitte AB has informed that
Per-Arne Pettersson will be auditor in charge.
Remuneration to the board of
directors and the auditor
The annual general meeting resolved that the total fees to the
board of directors will amount to SEK 1,100,000, excluding
remuneration for committee work, of which SEK 350,000 will be paid
to the chairman and SEK 150,000 to each of the other members
elected at the annual general meeting. SEK 50,000 will be paid for
work performed by the chairman of the audit committee and no
remuneration will be paid to the other members. No remuneration
will be paid to the members of the remuneration committee.
The annual general meeting resolved that fees to
the auditor shall be paid according to approved invoice.
Guidelines for remuneration for
senior executives
The annual general meeting resolved in accordance with the board of
directors' proposal on guidelines for remuneration for senior
executives.
Authorization of the board to
issue new shares
The annual general meeting resolved to authorize the board to issue
shares corresponding to not more than 10 per cent of the total
number of shares in the company, with or without deviation from
the shareholders' preferential rights, with the
purpose to raise new capital and to take advantage of future
opportunities to attract new long-term owners of strategic
importance to the company, to finance the company's growth
strategy, as well as to enable the company to acquire the remaining
minority shares in the subsidiary Zymetech ehf. by way of issue in
kind.
For
more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a life science company that
develops and sells medical devices for infection-related diseases.
The products are based on a barrier technology that includes marine
enzymes. The Company's first product is ColdZyme® Mouth Spray,
which can prevent colds and reduce the duration of disease. The
product has been launched in around ten markets. The strategy is to
continue to grow by strengthening the Company's position in
existing markets and expanding into new geographic markets through
established partners. The company is headquartered in Lund and is
listed on Nasdaq First North. For more information please
visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser
Bank.
Enzymatica Bulletin AGM 26 April
2018
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
Grafico Azioni ENZYMOTEC LTD. (NASDAQ:ENZY)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni ENZYMOTEC LTD. (NASDAQ:ENZY)
Storico
Da Set 2023 a Set 2024